Randomized, open, multicenter study to evaluate the antiviral activity, safety and pharmacokinetics of ABT-450, with ritonavir (ABT-450 / r) in combination with ABT-267 and / or ABT-333, with or without ribavirin ( RBV), for 8, 12 or 24 weeks to patients with chronic hepatitis C virus genotype 1 infection who have not received prior treatment or no responders
Pathology and candidate patients
Dr. Moises Diago
Hospital Quirónsalud Valencia.
June 18, 2012
Hospital Quirónsalud valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: firstname.lastname@example.org